RecruitingNCT06445322
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
Sponsor
Ascidian Therapeutics, Inc
Enrollment
50 participants
Start Date
Jun 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Eligibility
Min Age: 5 Years
Inclusion Criteria2
- Presence of mutations in the ABCA4 gene
- ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
Exclusion Criteria3
- The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
- Retinal disease other than ABCA4-related retinopathy
- Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTPrescreening Assessments
Various genetic and visual assessments.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06445322
Related Trials
Inherited Retinal Degenerative Disease Registry
NCT024359401 location
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT074255745 locations
Oral Metformin for Treatment of ABCA4 Retinopathy
NCT045457362 locations
Adaptive Optics Imaging of Outer Retinal Diseases
NCT053554152 locations
Study of ALK-001 on the Progression of Stargardt Disease
NCT074193343 locations